Nexus Medical Partners

Zipit Wireless, Inc. is a technology company based in Greenville, South Carolina, specializing in critical messaging and Internet of Things (IoT) solutions. Founded in 2007, the company provides instant communication services designed for critical situations, catering to various sectors such as healthcare, education, government, and hospitality. Its Enterprise Critical Messaging Solution enables two-way communication for organizations, enhancing operational efficiency during emergencies. Additionally, Zipit offers cloud-based software and cellular services that support the management of connected devices, including wireless trail cameras and medication adherence devices. The company's subscription platform facilitates cellular activation and provides comprehensive business reports, allowing enterprises to streamline their operations and manage mobile workers effectively. Zipit Wireless markets its innovative software and services on a global scale, helping clients navigate the complexities of IoT connectivity.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Sabal Medical is a healthcare platform focused on enhancing the safety and efficiency of medication administration in hospitals and long-term care facilities. By connecting nurses and pharmacists, the company provides innovative technology that includes mobile medication tracking services utilizing bar code verification. This approach ensures that patients receive the correct medications and proper dosages at the appropriate times, thereby improving overall healthcare delivery and patient safety.

Zipit Wireless, Inc. is a technology company based in Greenville, South Carolina, specializing in critical messaging and Internet of Things (IoT) solutions. Founded in 2007, the company provides instant communication services designed for critical situations, catering to various sectors such as healthcare, education, government, and hospitality. Its Enterprise Critical Messaging Solution enables two-way communication for organizations, enhancing operational efficiency during emergencies. Additionally, Zipit offers cloud-based software and cellular services that support the management of connected devices, including wireless trail cameras and medication adherence devices. The company's subscription platform facilitates cellular activation and provides comprehensive business reports, allowing enterprises to streamline their operations and manage mobile workers effectively. Zipit Wireless markets its innovative software and services on a global scale, helping clients navigate the complexities of IoT connectivity.

Zipit Wireless, Inc. is a technology company based in Greenville, South Carolina, specializing in critical messaging and Internet of Things (IoT) solutions. Founded in 2007, the company provides instant communication services designed for critical situations, catering to various sectors such as healthcare, education, government, and hospitality. Its Enterprise Critical Messaging Solution enables two-way communication for organizations, enhancing operational efficiency during emergencies. Additionally, Zipit offers cloud-based software and cellular services that support the management of connected devices, including wireless trail cameras and medication adherence devices. The company's subscription platform facilitates cellular activation and provides comprehensive business reports, allowing enterprises to streamline their operations and manage mobile workers effectively. Zipit Wireless markets its innovative software and services on a global scale, helping clients navigate the complexities of IoT connectivity.

Sabal Medical is a healthcare platform focused on enhancing the safety and efficiency of medication administration in hospitals and long-term care facilities. By connecting nurses and pharmacists, the company provides innovative technology that includes mobile medication tracking services utilizing bar code verification. This approach ensures that patients receive the correct medications and proper dosages at the appropriate times, thereby improving overall healthcare delivery and patient safety.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Selah Technologies, LLC is an advanced materials manufacturing company developing and commercializing two proprietary nanotechnologies. Selah Dotsâ„¢ are patent-pending photoluminescent carbon-based nanoparticles. Selah Tubesâ„¢ are enriched single-walled nanotubes with precisely engineered electronic properties protected under US Patent No. 7,374,685. Our mission is to consistently deliver high quality nanomaterials and nano-enabled products to the global marketplace. Our growth strategy is to leverage relationships with market leading companies to establish mutually beneficial joint research and development agreements. Our strategy is founded in the conviction that early successes in our target markets will occur via exploitation of nanomaterials in established applications in which their incorporation is both useful and compelling, and addresses needs that nanotechnology can fulfill either immediately or in the very short term.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, dedicated to the discovery and development of small-molecule antiviral therapeutics. Founded in 2006, the company primarily focuses on creating therapies for viral infections, with a significant emphasis on hepatitis C virus (HCV) and HIV. Its product portfolio features pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target the NS5A and NS5B proteins of HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be combined with other antiviral classes to address viral resistance, thus providing patients with effective treatment options against various hepatitis genotypes. The company has raised over $27 million from several investors to support its research and development efforts.

Cequent Pharmaceuticals is an early-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative RNA interference (RNAi)-based therapeutics to prevent and treat various human diseases, including inflammatory conditions and cancer. The company utilizes its proprietary TransKingdom RNA interference (tkRNAi) technology, designed to safely and effectively deactivate specific genes associated with diseases using non-pathogenic bacteria to deliver RNAi directly into cells. Currently, Cequent's lead drug candidates, which target colon cancer prevention and inflammatory bowel disease, are in pre-clinical development. Established in 2006, Cequent originated from pioneering research at the Institut Pasteur in Paris and the Beth Israel Deaconess Medical Center/Harvard Medical School. In 2010, the company was acquired by Marina Biotech, Inc.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.

Magellan Diagnostics, Inc. is a medical device company focused on developing and manufacturing point-of-care systems and clinical laboratory instruments for lead testing. The company offers a range of products, including LeadCare II, a blood lead testing system, and LeadCare Ultra, designed for laboratory use. Additionally, LeadCare Plus serves facilities with lower testing volumes. Magellan also provides analytical services related to lead and heavy metal exposure, aiding in the monitoring of exposure for employees and the general public. Founded in 2004 and headquartered in Billerica, Massachusetts, Magellan has its roots in the late 1960s with the development of a novel blood lead measurement technique by MIT graduates. The company has since evolved to create portable instruments that enhance accessibility to lead testing in various settings, helping to identify and protect individuals at risk of lead exposure.

Neurotech is a privately held biotechnology company focused on developing innovative therapies for chronic retinal diseases, addressing significant unmet medical needs in the ophthalmology market. The company has created a novel ocular implant that facilitates the continuous production of therapeutic proteins directly in the eye. This system is designed to help therapeutic cells survive in challenging conditions, thereby replacing or supporting the function of deteriorating target cells or tissues. By enhancing the treatment options available for eye diseases, Neurotech aims to improve the quality of life for patients suffering from these conditions.

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.